Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW Trial
Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary FibrosisCompany on track to report initial topline data in 2H 2026
Rein Therapeutics is testing a new breathing medicine for a serious lung disease and just added Germany to their study—a sign they're making progress and expanding their reach. When a company advances its medicine testing like this, it shows confidence, though remember that drug tests can still fail before they finish.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.